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 Recipients of haploidentical transplantation may have a lower degree of 
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higher degree of HLA mismatches did not have any impact on outcome  
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HIGHLIGHTS 
 Recipients of haploidentical transplantation may have a lower degree 
of HLA disparity, both global or in one-way allo-immune response 
 Higher degree of HLA mismatches did not have any impact on OS, 
NRM, aGVHD, cGVHD ,relapse, graft failure.  
 Advanced disease was the most significant predictor of poor outcome. 
 
Abstract 
We studied the impact of HLA mismatching on the outcome of 318 consecutive 
patients who received an un-manipulated haploidentical bone marrow 
transplant, followed by post-transplant cyclophosphamide (PT-CY). The 
number of HLA mismatched antigens was tested for its impact on overall 
survival (OS) and non relapse mortality (NRM), whereas HLA mismatches in 
the graft versus host (GvH) direction  were tested for prediction of GvHD  and 
relapse;  finally,  we studied whether graft rejection  correlated with the 
number of HLA mismatched antigens in host versus graft (HvG) direction.  
Two-hundred and thirty-one donor/recipient pairs (72%) had 4/8 mismatches 
at the A, B, C, DRB1 HLA loci. HLA mismatches did not predict the 2 years 
OS(HR 0.83, p=0.58) and NRM(SHR 1.08, p=0.93). The cumulative 
incidence of aGvHD (p=0.13), 1-year cGvHD (p=0.84), and relapse rate 
(p=0.26) did not correlate with univectorial GvH mismatches. 
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Similarly,no correlation was observed between the amount of HLA mismatch in 
the HvG direction and graft rejection.  
In multivariate analysis, advanced disease at transplant was the strongest 
predictor of survival, NRM, relapse, and graft rejection.  
In conclusion: the degree of HLA mismatching should not be used asa criterion 
to select family haplo-identical donors when using bone marrow as stem cell 
source and PT-Cy for GvHD prophylaxis. 
 
Keywords: haploidentical transplantation; HLA disparity; post-transplant 
cyclophosphamide 
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Introduction 
 
Human leukocyte antigen (HLA) compatibility is the crucial requirement to 
perform an allogeneic hematopoietic stem cell transplantation (HSCT), and it 
remains the most meaningful predictor of long-term survival(1–3). Indeed, in 
patients undergoing HSCT, the number ofmismatched HLA is associated with 
higher rates of graft versus host disease (GvHD) and of non-relapse mortality 
(NRM)(3–5). Registry data have clearly demonstrated that even a single 
HLAmismatch may impact NRM, mostly due to increased GvHD or 
rejection(6,7). For this reason, in the presence of one or more HLA-
mismatches (whether the donor is related or unrelated),GvHD prophylaxis is 
enhanced with pre-transplant anti-lymphocyte globulinor other lymphocyte-
depleting agents(8–13).Nevertheless, the outcome of HSCT from mismatched 
donors remains less satisfactory, even if few studies have shown that the 
presence of HLA mismatchmay reduce relapse rate(14–16). These data 
discouraged the use of HSCT from donors with higher HLA-disparity (e.g., 
partially matched donors); indeed, HSCT from haploidentical related donors 
resulted in a high risk of rejection and of GvHD, with obvious impact on NRM, 
especially when HSC source is T-cell replete(2,17,18). 
In recent years, different strategies have been adopted to improve the 
outcome of haploidentical HSCT, including protocols of graft manipulation in 
vitro (i.g. T-cell depleted HSCT)(19–22)and increased immunosuppression in 
vivo (i.e., T-cell repleted HSCT)(23–27). Among these, the use of post-
transplant high dose cyclophosphamide (PTCy) allowed a large number of 
patients to receive a haploidentical T repleted HSCT, with acceptable GvHD and 
NRM and excellent long-term outcome(28–31).    
HLA genes are inherited within parental haplotypes, which represent groups of 
physically linked alleles with possible conserved association due to positive 
“linkage disequilibrium”(32). By definition, “HLA-haplo-identical transplant’’ 
means that familiardonor and recipient share only one inherited HLA-
haplotype, while the second one is different and randomly derived.As a result, 
HLA disparity is supposed to be 50% (4 out of 8 HLA alleles, considering the 
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HLA-A, -B, -C and –DRB1 loci) if the HLA alleles in the non-shared haplotypes 
are completely different. However, possible casual identity of some HLA alleles 
(due to a random heritage of homozygous allelesin the donor or in the 
recipient) may account for a lower degree of disparity. As a result, in some 
donor/recipient pairs the degree of disparity is less than the predicted 4 over 8 
HLA alleles.  
 
Furthermore, HLA incompatibility should be considered in a bi-directional 
fashion; the vector of incompatibility can certainly be seen from either the 
donor perspective (graft-versus-host, GvH direction) or from the recipient 
perspective (host-versus-graft, HvG direction). From the donor’s perspective, 
the presence of recipient HLA-A, -B, -C, and -DRB1 differences not shared by 
the donor stimulates the donor anti-host allo-response or GvH recognition that 
is associated with higher risks of GvHD compared with complete matching. 
Conversely, from the patient’s perspective, the presence of donor disparity not 
shared by the recipient provokes the HvGallo-response that increases the risk 
of graft failure. Thus, in the case of homozygosis of some HLA loci, reduced 
HLA-disparity may involve only one vector of the allo-immune response; this 
may affect GvHallo-response in the case of homozygosis of the recipient, or 
HvGallo-response in the case of homozygosis of the donor(32).  
 
Even if it is now well established that PTCy allows a safe enough HSCT 
procedure across the HLA-barrier, we wondered whether a different HLA-
matching may account for different outcome in the context of haploidentical 
bone marrow transplant (BMT). In this paper we report on 318 consecutive 
patients with high-risk disease and lacking an HLA identical donor, who 
received a BMT from a haplo-identical relatives in two Italian institutions after 
the same conditioning and GvHD prophylaxis regimen. This large series offers 
the opportunity to verify: 1) the effective degree of HLA mismatchbetween 
donor and recipient and 2) the possible impact of actual lower HLA disparity on 
HSCT outcome.
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Patients and Methods 
We analyzed 318 consecutive patients with hematological malignancies 
transplanted in Genoa and Naples.All patients or their legal guardians signed 
approved informed consent to use their transplant data for clinical research as 
per EBMT standard before proceeding to transplantation. Patients were 
transplanted from August 2010 to July 2016 from a relatedhaploidentical 
donor, after receiving a myeloablative-conditioning regimen and GvHD 
prophylaxis as described below. Main eligibility criteria were: 1. Age 18-70 
years; 2. Hematological malignancy with high risk of relapse (active disease at 
time of transplant was allowed); 3. Lack of a sibling HLA-identical donor; 4. 
Lack of an HLA-matched unrelated donor (at least 7/8) or suitablecord blood 
unit (at least 4/6, with ≥2 x 107 total nucleated cells [TNC]/kg) available in a 
clinically meaningful timeframe. Of these 318 patients, 294 were treated at 
San Martino Hospital in Genoa and 24 at Federico II University in Naples.  
Donor selection 
The best related haploidentical donor was selected according to the following 
algorithm: 1. Donor health; 2.Donor age; 3. CMV status (as compared to 
recipient’s); 4. AB0-compatibility.The possibledifferent number of HLA-
mismatches and relationship were not used as a criterion for donor selection. 
Conditioning regimen  
The myeloablative conditioning regimen was basedon either total body 
irradiation (TBI) or chemotherapy.  TBI was given in three days (-8 to -6) at 
the total dose of 990 cGy or 1200 cGy(300 daily x 3, or 200 bi-daily x 3, 
respectively) and fludarabine 120 mg/m² in four days (-5 to -2) (n=56). The 
chemotherapy-only regimen consisted of: 1)Thiotepa 10 mg/kg in two days (-
6-5), followed by fludarabine 150 mg/m² and Busulfan 9.6 mg/kg 
intravenously for three days (-4 to -2) (n=125). For patients aged more than 
60 years, or patients with comorbidities or poor clinical condition, the dose of 
Busulfan was reduced to 6.4 mg/kg (one day was omitted)(n=120). 2)  
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Thiotepa 10 mg/kg in two days, Fludarabine 50 mg/m² for three days, and 
Melphalan 70 mg/m2 (with myeloma or for patients previouslyautografted with 
Busulfan) (n=17).  
GvHD prophylaxis 
GvHD prophylaxis consisted of: 1. Post-transplant cyclophosphamide 50 mg/kg 
given on day +3 and +5; 2. cyclosporine A (CsA) 1 mg/kg given as a 
continuous iv infusion from days 0 to +20, adjusted for blood levels (200–400 
ng/ml), and then orally until the day +180; 3. Mycophenolatemofetil (MMF) 
given orally at the dose of 15 mg/kg every 12 hours from day +1 to day +28. 
Mesna was administered according to institutional policies, at the minimum 
dose of 80% of the cyclophosphamide dose. 
Stem cell source and transplantation 
Un-manipulated bone marrow was used as stem cell support at day 0. Donors 
underwent bone marrow harvest under general anesthesia (Genoa) or epidural 
anesthesia (Naples) and the ideal target of total nucleated cells was 4 x 108/kg 
of recipient body weight. Pegylated-G-CSF 6 mg subcutaneouswasgiven on day 
+6 to all patients. 
HLA typing 
Donors and recipients were typed, until December 31st 2015, using DNA 
method (SSO and SBT) for HLA A, B, C, DRB1, DQ and DPB at a highresolution 
level, as defined by EFI standards.Starting from January 2016, HLA typing was 
doneby NGS at allelic level for the same loci. When applicable (72.3% of 
patients), other first- or higher-degree family members were typed to 
definitively establish haplotype identity and heritage. 
Supportive care 
Anti-infectious prophylaxis was started during the conditioning regimen and 
consisted of acyclovir 500 mg/m2 three times a day, levofloxacin 500 mg a 
day, and fluconazole until day +75 (or mold-active prophylaxis for high-risk 
patients). Bi-weekly CMV monitoring, by PCR or antigenemia, was started on 
Page 7 of 30
8 
day −7, until day +100, and weekly until day +180. Patients received red 
blood cell and platelet transfusions according to institutional protocols. 
Diagnosis and treatment of GvHD 
The diagnosis of acute and chronic GvHD was mainly clinical, based on 
standard criteria(33,34), and confirmed, when possible, by histological analysis 
of skin and/or rectal biopsy specimens. First-line and second-line therapy for 
GvHD was provided according to institutional protocols. 
 
Graft failure 
Graft failure was defined as persistent pancytopenia with lack of donor 
chimerism (i.e., <5% donor) by day +30 from transplantation.  
 
Assessment of HLA disparity 
We assessed HLA incompatibility based on the total number of HLA 
mismatchesand their direction in each donor/recipient pair, and their 
correlation with the transplant outcomes. HLA mismatch in the GvH direction 
was defined as the presence of host antigens or alleles not shared by the 
donor. HLA mismatch in the HvG direction was defined as the presence of 
donor antigens or alleles not shared by the host. We evaluated overall survival 
(OS) and non-relapse mortality (NRM) according to the amount of overall 
mismatches; also, we analyzed cumulative incidence (CI) of grade II – IV 
acute GvHD (aGvHD), moderate-severe chronic GvHD (cGvHD), and 
cumulative incidence of relapse according to the degree of HLA mismatch in 
the GvH direction and graft rejection rate according to the degree of HLA 
mismatch in the HvG direction. For analysis purposes, the whole patient 
population was divided into 2 groups according to the number of HLA 
mismatch: 0-1-2 allele or antigen mismatches versus 3-4 allele or antigen 
mismatches (35). The same groups (0-2 versus 3-4 HLA mismatches) were 
also generated when analyzing vectorial HLA-disparity, either in the GvH or 
HvG direction. The analysis were performed grouping patients in 0-3 vs 4 
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mismatches, bidirectional for OS and NRM, and monodirectional for GVHD and 
relapse (GvH vector) and graft failure (HvG vector). 
Endpoints and statistical methods  
Overall survival was estimated using the Kaplan-Meier approach; OS is defined 
as time from starting HSCT to death from any cause, or the last follow-up for 
living patients.Cumulative incidence analysis was used for NRM,  relapse, and 
GvHD incidence (either acute or chronic). NRM is defined as death due to any 
cause other than progression of the underlying malignancy, with death due to 
relapse as competing event. Relapse is defined as recurrence of the underlying 
hematological malignancy; death due to any other cause (NRM) was a 
competing event for this analysis. 
For GvHD cumulative incidence analysis, death without aGvHD in first 100 days 
was considered a competing event for aGvHD endpoint, while relapse or death 
in absence of cGvHD were considered as competing events for cGvHD 
outcome.  
Association of mismatch and other demographic and clinical characteristics 
with overall survival was assessed using the univariable semiparametric Cox 
regression model, while the Fine and Gray model for competing risk was 
adopted to test the association with cumulative incidence of aGvHD, cGvHD, 
relapse, and NRM.   
A univariable logistic regression model to determine association of 
demographic and clinical characteristics with rejection event was used.  
The total number of mismatch was considered for OS and NRM, mismatch in 
GvHD direction was assessed for relapse, cGvHD, and aGvHD, while mismatch 
in HvG direction was considered for reject endpoint.  
Hazard-ratios (HR) for the Cox model, Sub-hazard ratio (SHR) for the Fine and 
Gray model, and Odds-ratio (OR) for the logistic regression model were 
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estimated and reported together with the corresponding 95% confidence 
interval (95% CI) to quantify the effect of single characteristics on outcomes.   
For each outcome, a multivariable regression model was subsequently 
performed. All variables with a univariable p-value < 0.15 were considered for 
the stepwise selection, and those that werestatistically significant were 
included in the final, multivariable model.   
A p-value ≤0.05 was considered statistically significant. Stata (v.13; 
StataCorp) was used for the computation.  
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Results  
Patients’ characteristics 
Complete baseline characteristics of transplanted patients are outlined in table 
1 for all patients and according to the number of HLA mismatch. The main 
clinical features were balanced between the mismatch groups except for GvH 
direction group, which had more patients in an advanced phase of disease at 
transplant in the high mismatch group.   
Median age of the 318 patients was 48 years (range 17-74). The patients were 
transplanted for the following underlying disease: acute myeloid leukemia 
(AML; n=130), acute lymphoblastic leukemia (ALL; n=64), lymphoproliferative 
disorders (LPD; n=43), chronic myeloproliferative neoplasm (CMPN; n=48), 
and myelodysplastic syndrome (MDS; n=33). About half of the patients 
(n=144, 45%) were in an advanced phase of disease at time of transplant.  
 
HLA mismatches 
Among the 318 donor/recipient pairs, 231 (73%) had 4/8 mismatches(A,B, C, 
and DRB1), but only 128(40%)had 4/8 “bidirectional” mismatches, while the 
remaining pairs shared one or more identical alleles at the examined HLA loci. 
Two- hundred and ninety-sixpatients(93%)presented a high number of HLA-
mismatches (3 and 4; n= 65 and 231, respectively) with donor and 22 (7%) 
presented a low number (0-1-2). Table 2 reports in detail the number of total 
HLA-mismatch, as well as the degree of one-way incompatibility in GvH vector 
(3-4 HLA-mismatch=264, 83%; 0-1-2 HLA-mismatch=54, 17%) and HvG 
vector (3-4 HLA-mismatch=272, 85%; 0-1-2 HLA-mismatch= 46, 15%)of 
these 318 donor/recipient pairs.  
The impact of HLA disparity (at HLA –A, -B, -C,-DRB1)was assessed in 
univariate analysis, taking into account the number of HLA mismatches (mm) 
as a discrete variable (0-2 vs 3-4 and 0-3 vs 4) and as a continuous variable 
(i.e.0,1,2,3,4 any direction;GvH vector and HvG vector, respectively). 
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Transplant outcome  
With a median follow up of 562 days (range 6-2241 days), 2-year OS was 58% 
(95% CI 52.5- 64%). Causes of deaths were relapse of disease for 74 (23%) 
patients and NRM for 61patients (18.8%) (infections: 38, hemorrhage: 7, 
GVHD: 12, endothelial complications:4). 
Cumulative incidence of NRM was  16% (95% CI 12.1-20.2%)  at  1 year. 
Cumulative incidence of relapse was 29.8% (95% CI 24.7-35.1%)at  2 years. 
Cumulative Incidence of aGvHD grade II-IV was 17.2% (95% CI:12.8%-
22.1%)after 100 days from transplant with a rate of aGVHD grade III – IV of 
5% (18 patients). 
Cumulative incidence of moderate and severe cGvHD at 1 year was  13.9% 
(95% CI 10.1-18.4%). Graft failure occurred in 21 patients (6.6%). 
 
 
 
OverallSurvival and Non Relapse Mortality 
In univariate analysis,having more HLA differences was not associated with 
worse OS (fig. 1a) nor with increased NRM  (fig.1b) (tab3), irrespective of 
whether they were analyzed as discrete (either 0-2 vs 3-4 mm and 0-3 vs 4 
mm) or continuous variable. The variable associated with worse OS was an 
active disease at transplant (HR 3.61, p<0.001). Were predictive of  NRM  
older age (SHR 1.03, p=0.002) and active disease at transplant (SHR 2.44, 
p<0.001). Multivariate analysis confirmed these data for OS and NRM (tab.4). 
Acute GvHD and Chronic GVHD 
In univariate analysis, having more HLA differences was not associated with a 
statistical difference in the risk of acute GvHD grade II – IV (Fig.2a) and 
chronic GVHD (fig.2b) (tab 5). The lack of association was observed when HLA 
mm were used as a discrete variable as well as when HLA mm was treated as a 
continuous variable, even if in this latter condition there was a trend for higher 
risk of aGvHD with increasing number of mismatches. 
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None of the other transplant variables included in univariate analysis were 
predictive of acute or chronic GVHD.  
Relapse 
In univariate analysis, having more HLA differences was not associated with a 
statistical difference in the risk of relapse rate (Fig. 3) (Tab 5). The lack of 
association was observed when HLA mm were used as a discrete variable (both 
0-2 vs 3-4 and 0-3 vs 4 mm), as well as when HLA mm was treated as a 
continuous variable. The variables associated with relapse were conditioning 
regimen (p=0.05) and active disease at transplant (HR 2.68, p<0.001). Also in 
multivariate analysis, conditioning regimen (p=0.035) and active phase of 
disease at transplant (HR 2.86, p<0.001) were associated with disease relapse 
(tab.4).  
Graft failure 
The number of patients who have less HLA mismatches with a donor was not 
protected from rejection. The variables associated with graft rejection were 
conditioning regimen (p=0.0078), active disease at transplant (HR 3.26, 
p=0.018), and older age (SHR 1.05, p=0.02) (tab 6). In multivariate analysis, 
graft rejection was associated with conditioning regimen (p=0.042)and with 
active disease at transplant (HR 2.79, p=0,05)(tab.4). 
. 
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Discussion 
In this study, we have analyzed the actual degree of HLA mismatchesin the 
context of haploidentical HSCT, and its possible impact on transplant outcome. 
In our analysis, only 73% of donor/recipient pairs were mismatched for all 4 
loci of the non-shared HLA haplotype. Thus, a significant proportion of 
transplants defined as haploidentical within the recent literature are more than 
half-matched, and may be better reported including their actual HLA disparity. 
However, this information does not clearly emerge from available data, raising 
possible concerns about the interpretation of haplo-HSCT results. Indeed, the 
impact of this possible reduced degree of disparity is as yet unknown. Based 
on well-established knowledge of transplant biology, these patients are 
expected to have a better outcome, since in the setting of unrelated 
transplants there is an obvious dose-effect of the number of HLA-mismatches 
on most transplant outcomes(2–7). However, in our analysis, the degree of 
HLA incompatibility did not show any impact on OS, NRM, relapse, graft 
failure,or GvHD rates, even when vectorial HLA matching in the GvH or HvG 
directions was considered. A trend toward lower rates of aGVHD was found 
when HLA disparity was treated as a continuous variable but without any 
impact on all the other outcome parameters including OS. 
Our findings are in agreement with a previous retrospectiveanalysis performed 
on 185 patients by Kasamon et al(35), which showed that greater HLA 
disparity according to the number of mismatched HLA-antigens in any direction 
(GvH or HvG) did not appear to influence the overall outcome after bone 
marrow transplantation with a high-dose post-transplant 
Cyclophosphamide.This analysis was confirmed when HLA disparity was 
assessed as either total  HLA-mismatches or as mismatches according to 
specific vectors (mono-directional GvH or HvG HLA-mismatch). However, these 
data were generated in the context of a non-myeloablative HSCT platform; in 
contrast, all the patients included in this study received a myeloablative 
conditioning regimen. Furthermore, our platform of GVHD prophylaxis included 
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cyclosporine A started at day 0 (instead of day +5), and PTCy was delivered at 
day +3 and +5 (rather than +3 and +4). In this study we didn’t look for the 
possible contribution of individual HLA loci; indeed, the small number of 
patients with low mismatched and the absence of impact of the number of 
HLA-mismatch do not power our study for such analysis. Furthermore, the 
possible contribution of an individual locus may be different according to the 
remaining HLA disparity.. 
The lack of impact of different HLA disparity in our study is likely to not be 
specific for haploidentical donors, but rather to be embedded with the use of 
PTCy. Indeed, PTCy might level off HLA disparity in mismatched 
transplantation regardless of the type of donor, similarly to what already 
reported with other platforms exploited to overcome the HLA barrier in 
haploidentical HSCT (36-37). This effect of PTCy on GvHD prevention may be 
due to clonal deletion of allo-reactive T cells activating at time of 
transplantation and possibly to the preservation of T-regulatory cells, 
eventually shaping post-transplant immune reconstitution (38). In our cohort, 
the incidence of relapse was less than 30% at 3 years, again with no impact of 
HLA disparity; thus, these results may suggest that the graft versus leukemia 
(GvL) effect is spared, possibly together with anti-infectious protection (in our 
study, the rate of infectious complication was not increased; data not shown). 
In conclusion, these data support the idea that PTCy exhibits the property of 
overcoming the HLA barrier; however, residual GvHD may also develop 
through non-HLA antigens, such as minor histocompatibility antigens. It 
remains to be determine whether this anti-GvHD effect of PTCy may be 
extended to the context of other HSCT settings. Prospective clinical trials are 
needed to adequately investigate the possible impact of PTCy in the context of 
unrelated HSCT, or even HLA-identical related transplantations. 
Page 15 of 30
16 
 
References 
 
1.  Anasetti C, Hansen JA. Effect of HLA incompatibility in marrow 
transplantation from unrelated and HLA-mismatched related donors. 
Transfus Sci. 1994;15(3):221–30.  
2.  Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, et al. Effect 
of HLA incompatibility on graft-versus-host disease, relapse, and survival 
after marrow transplantation for patients with leukemia or lymphoma. 
Hum Immunol. 1990;29(2):79–91.  
3.  Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. 
High-resolution donor-recipient HLA matching contributes to the success 
of unrelated donor marrow transplantation. Blood. 2007;110(13):4576–
83.  
4.  Ciurea SO, Champlin RE. Outcomes of patients treated and one human 
leukocyte antigen-mismatched related compared with matched unrelated 
donors. Biology of Blood and Marrow Transplantation. 2011;17(8):1261.  
5.  Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, 
Horowitz M, et al. Impact of HLA class I and class II high-resolution 
matching on outcomes of unrelated donor bone marrow transplantation: 
HLA-C mismatching is associated with a strong adverse effect on 
transplantation outcome. Blood. 2004;104(7):1923–30.  
6.  Crocchiolo R, Ciceri F, Fleischhauer K, Oneto R, Bruno B, Pollichieni S, et 
al. HLA matching affects clinical outcome of adult patients undergoing 
haematopoietic SCT from unrelated donors: a study from the Gruppo 
Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor 
Registry. Bone Marrow Transplant. 2009;44(9):571–7.  
7.  Verneris MR, Lee SJ, Ahn KW, Wang H-L, Battiwalla M, Inamoto Y, et al. 
HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor 
Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An 
Analysis from the Center for International Blood and Marrow Transplant 
Research. Biol Blood Marrow Transplant. 2015;21(10):1783–9.  
Page 16 of 30
17 
8.  Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et 
al. Standard graft-versus-host disease prophylaxis with or without anti-T-
cell globulin in haematopoietic cell transplantation from matched 
unrelated donors: a randomised, open-label, multicentre phase 3 trial. 
Lancet Oncol. 2009;10(9):855–64.  
9.  Bacigalupo A, Oneto R, Lamparelli T, Gualandi F, Bregante S, Raiola AM, 
et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot 
study with antithymocyte globulin (ATG). Bone Marrow Transplant. 
2001;28(12):1093–6.  
10.  Abdel-Azim H, Mahadeo KM, Zhao Q, Khazal S, Kohn DB, Crooks GM, et 
al. Unrelated donor hematopoietic stem cell transplantation for the 
treatment of non-malignant genetic diseases: An alemtuzumab based 
regimen is associated with cure of clinical disease; earlier clearance of 
alemtuzumab may be associated with graft rejection. Am J Hematol. 
2015;90(11):1021–6.  
11.  Devillier R, Furst S, El-Cheikh J, Castagna L, Harbi S, Granata A, et al. 
Antithymocyte globulin in reduced-intensity conditioning regimen allows a 
high disease-free survival exempt of long-term chronic graft-versus-host 
disease. Biol Blood Marrow Transplant. 2014;20(3):370–4.  
12.  Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, et al. ATG 
prevents severe acute graft-versus-host disease in mismatched unrelated 
donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 
2011;17(8):1237–44.  
13.  Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, et al. 
Alemtuzumab levels impact acute GVHD, mixed chimerism, and 
lymphocyte recovery following alemtuzumab, fludarabine, and melphalan 
RIC HCT. Blood. 2016;127(4):503–12.  
14.  Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon J-D, et al. 
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-
donor haemopoietic-cell transplantation: a retrospective study. Lancet 
Oncol. 2012;13(4):366–74.  
15.  Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. 
Page 17 of 30
18 
Graft-versus-leukemia reactions after bone marrow transplantation. 
Blood. 1990;75(3):555–62.  
16.  Shaw BE, Mayor NP, Russell NH, Apperley JF, Clark RE, Cornish J, et al. 
Diverging effects of HLA-DPB1 matching status on outcome following 
unrelated donor transplantation depending on disease stage and the 
degree of matching for other HLA alleles. Leukemia. 2010;24(1):58–65.  
17.  Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ, et 
al. Mismatched family donors for bone-marrow transplantation as 
treatment for acute leukaemia. Lancet. 1983;1(8325):612–5.  
18.  Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, et al. Results 
of allogeneic bone marrow transplants for leukemia using donors other 
than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767–77.  
19.  Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, 
Dupont B, et al. Transplantation for severe combined immunodeficiency 
with HLA-A,B,D,DR incompatible parental marrow cells fractionated by 
soybean agglutinin and sheep red blood cells. Blood. 1983;61(2):341–8.  
20.  Jabado N, Le Deist F, Cant A, De Graeff-Meeders ER, Fasth A, Morgan G, 
et al. Bone marrow transplantation from genetically HLA-nonidentical 
donors in children with fatal inherited disorders excluding severe 
combined immunodeficiencies: use of two monoclonal antibodies to 
prevent graft rejection. Pediatrics. 1996;98(3 Pt 1):420–8.  
21.  Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, et al. 
Successful engraftment of T-cell-depleted haploidentical “three-loci” 
incompatible transplants in leukemia patients by addition of recombinant 
human granulocyte colony-stimulating factor-mobilized peripheral blood 
progenitor cells to bone marrow inoculum. Blood. 1994;84(11):3948–55.  
22.  Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. 
Treatment of high-risk acute leukemia with T-cell-depleted stem cells 
from related donors with one fully mismatched HLA haplotype. N Engl J 
Med. 1998;339(17):1186–93.  
23.  Lu D-P, Dong L, Wu T, Huang X-J, Zhang M-J, Han W, et al. Conditioning 
including antithymocyte globulin followed by unmanipulated HLA-
Page 18 of 30
19 
mismatched/haploidentical blood and marrow transplantation can achieve 
comparable outcomes with HLA-identical sibling transplantation. Blood. 
2006;107(8):3065–73.  
24.  Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti 
R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow 
transplantation for patients with high-risk hematologic malignancies. 
Blood. 2013;121(5):849–57.  
25.  Chen H, Liu K, Xu L, Chen Y, Han W, Zhang X, et al. Haploidentical 
hematopoietic stem cell transplantation without in vitro T cell depletion 
for the treatment of philadelphia chromosome-positive acute 
lymphoblastic leukemia. Biol Blood Marrow Transplant. 2015;21(6):1110–
6.  
26.  Huang X-J, Liu D-H, Liu K-Y, Xu L-P, Chen H, Han W, et al. Haploidentical 
hematopoietic stem cell transplantation without in vitro T-cell depletion 
for the treatment of hematological malignancies. Bone Marrow 
Transplant. 2006;38(4):291–7.  
27.  Huang W-R, Li H-H, Gao C-J, Bo J, Li F, Dou L-P, et al. Haploidentical, 
unmanipulated G-CSF-primed peripheral blood stem cell transplantation 
for high-risk hematologic malignancies: an update. Bone Marrow 
Transplant. 2016;51(11):1464–9.  
28.  Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable 
engraftment of major histocompatibility complex-incompatible cells after 
nonmyeloablative conditioning with fludarabine, low-dose total body 
irradiation, and posttransplantation cyclophosphamide. Blood. 
2001;98(12):3456–64.  
29.  Luznik L, O’Donnell P V, Symons HJ, Chen AR, Leffell MS, Zahurak M, et 
al. HLA-haploidentical bone marrow transplantation for hematologic 
malignancies using nonmyeloablative conditioning and high-dose, 
posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 
2008;14(6):641–50.  
30.  Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, 
et al. Unmanipulated Haploidentical Bone Marrow Transplantation and 
Page 19 of 30
20 
Posttransplantation Cyclophosphamide for Hematologic Malignancies after 
Myeloablative Conditioning. Biol Blood Marrow Transplant. 
2013;19(1):117–22.  
31.  Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, 
et al. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell 
Transplantation Is a Safe and Effective Alternative to Unrelated Donor 
Transplantation in Patients Without Matched Sibling Donors. Biol Blood 
Marrow Transplant. 2015;21(7):1299–307.  
32.  Petersdorf EW. Mismatched unrelated donor transplantation. Semin 
Hematol. 2016;53(4):230–6.  
33.  Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et 
al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow 
Transplant. 1995;15:825–8.  
34.  Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. 
National Institutes of Health Consensus Development Project on Criteria 
for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 
Diagnosis and Staging Working Group report. Biol Blood Marrow 
Transplant. 2015;21(3):389–401.e1.  
35.  Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai H-L, Bolanos-Meade J, 
et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation 
with high-dose posttransplantation cyclophosphamide: effect of HLA 
disparity on outcome. Biol Blood Marrow Transplant. 2010;16(4):482–9.  
36.   Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell     
       transplantation without in   vitro T-cell depletion for the treatment of  
       hematological malignancies. Bone Marrow Transplant. 2006;38(4):291– 
       297.  
37 Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor 
for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 
2016 Apr 12;9:35.  
38.  Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakry CG, Blazar BR, Levy 
RB, et al. Donor CD4+ Foxp3+ regulatory T cells are necessary for 
posttransplantation cyclophosphamide-mediated protection against GVHD 
Page 20 of 30
21 
in mice. Blood. 2014;124(13):2131–41.  
 
 
 
Figure 1a: Kaplan & Meier probability of overall survival after myeloablative 
conditioning. Low mismatch vs. high mismatch. p= 0.58 
Figure 1b: Cumulative incidence of non-relapse mortality after myeloablative 
conditioning. Low mismatch vs. high mismatch. p= 0.93 
 
Figure 2a: Incidence of grade II-IV acuteGvHD after myeloablative 
conditioning. Low mismatch vs. high mismatch. p= 0.13 
Figure 2b: Cumulative incidence of moderate-severe chronic GvHD after 
myeloablative conditioning. Low mismatch vs. high mismatch. p= 0.84 
 
Figure 3: Cumulative incidence of relapse. Low mismatch vs. high mismatch 
after myeloablative conditioning. p= 0.26 
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Table 1. Clinical characteristics of patients (numbers in bracket indicate %;+ 
indicates standard deviation. **: p=0.004; 
Demographic and 
clinical 
characteristics 
Allpatients 
(N = 318) 
Low mm 
(0-2) 
(n=22) 
High mm 
(3-4) 
(n=296) 
Low mm 
GvH  (0-
2) 
(n=54) 
High mm 
GvH  (3-4) 
(n=264) 
Low mm 
HvG  (0-
2) 
(n=46) 
High mm 
HvG (3-
4) 
(n=272) 
Male gender,  n (%) 172 (54.1) 14 (63.6) 158 (53.3) 33 (61.1) 139 (52.7) 24 (52.2) 148 (54.4) 
Age 48 + 14.9 51.4 + 
12.7 
47.7 + 15 51.5 + 
11.2 
47.3 + 15.4 49.6 + 
13.2 
47.7 + 
15.1 
Male gender donor 
n(%) 
193 (60.7) 13 (59.1) 180 (60.8) 37 (68.5) 156 (59.1) 28 (60.9) 165 (60.7) 
Donor mother 27 (8.5) 1 (4.6) 26 (8.8) 2 (3.7) 25 (9.5) 3 (6.5) 24 (8.8) 
Disease         
- AML 130 (40.9) 8 (36.4) 122 (41.2) 16 (29.6) 114 (43.2) 16 (34.7) 114 (41.9) 
- ALL 64 (20.1) 2 (9.1) 62 (21) 4 (7.4) 60 (22.7) 8 (17.4) 56 (20.6) 
- NHL 20 (6.3) 3 (13.6) 17 (5.8) 8 (14.8) 12 (4.5) 4 (8.7) 16 (5.9) 
- CLL 10 (3.1) 1 (4.6) 9 (3) 4 (7.4) 6 (2.3) 2 (4.4) 8 (2.9) 
- MM 13 (4.1) 2 (9.1) 11 (3.7) 3 (5.6) 10 (3.8) 2 (4.4) 11 (4.1) 
- MPD 48 (15.1) 3 (13.6) 45 (15.2) 13 (24.1) 35 (13.3) 6 (13) 42 (15.4) 
- MDS 33 (10.4) 3 (13.6) 30 (10.1) 6 (11.1) 27 (10.2) 8 (17.4) 25 (9.2) 
Active disease at BMT 144 (45.3) 12 (54.6) 132 (44.6) 34 (63) 110 
(41.7)** 
21 (45.7) 123 (45.2) 
TNC infused 1-unit incr. 3.38 + 1.16 3.55 + 
1.31 
3.36 + 
1.15 
3.49 + 
1.17 
3.35 + 1.16 3.3 + 1.2 3.4 + 1.1 
AB0 major 
incompatibility 
62 (19.5) 5 (22.7) 57 (19.3) 9 (16.7) 53 (20.1) 10 (21.7) 52 (19.1) 
CMV serology (don/rec)         
+/+ 200 (62.9) 14 (63.6) 186 (62.8) 34 (63) 166 (62.9) 30 (65.2) 170 (62.5) 
      +/- 20 (6.3) 1 (4.5) 19 (6.4) 2 (3.7) 18 (6.8) 4 (8.7) 16 (5.9) 
      -/+ 73 (23) 6 (27.3) 67 (22.7) 15 (27.8) 58 (22) 8 (17.4) 65 (23.9) 
      -/- 25 (7.8) 1 (4.6) 24 (8.1) 3 (5.5) 22 (8.3) 4 (8.7) 21 (7.7) 
Conditioning regimen        
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     TT FluBu (2 days) 120 (37.6) 11 (50) 109 (36.8) 23 (42.6) 97 (36.7) 18 (39.1) 102 (37.5) 
     TT FluBu (3 days) 125 (39.3) 7 (31.8) 118 (39.9) 21 (38.9) 104 (39.4) 20 (43.5) 105 (38.6) 
     TBI 330x3 Flu 38 (12) 0 (0) 38 (12.8) 5 (9.3) 33 (12.5) 2 (4.4) 36 (13.2) 
     TBI 200x2 Flu 18 (5.7) 1 (4.6) 17 (5.8) 2 (3.7) 16 (6.1) 3 (6.5) 15 (5.5) 
     TT Flu Mel 17 (5.4) 3 (13.6) 14 (4.7) 3 (5.5) 14 (5.3) 3 (6.5) 14 (5.2) 
Abbreviations: mm=mismatched;AML=acute myeloidleukemia; ALL=acute 
lymphoblasticleukemia; NHL=non-Hodgkin’slymphoma; 
CLL=chroniclymphocyticleukemia; MM= multiple myeloma; MPD=myeloproliferative 
disease; MDS=myelodysplasticsyndrome; TNC=totalnucleatedcells; 
CMV=citomegalovirus; TT=thyotepa; Flu=fludarabine; Bu=busulfan; TBI=total body 
irradiation; Mel=melphalan 
 
 
 
Table 2.  HLA mismatches 
Number of HLA 
mismatched 
Total  HLA 
mismatched # (%) 
HLA mismatched 
GVH direction 
HLA mismatched 
HVG direction 
4 antigen 231 (73%) 164 (52%) 185 (58%) 
3 antigen 65 (20%) 100 (32%) 87 (28%) 
2 antigen 14 (4%) 36 (11%) 33 (10%) 
1 antigen 5 (2%) 10 (3%) 6 (2%) 
0 antigen 3 (1%) 8 (2%) 7 (2%) 
Abbreviations: GVH=graft vs host; HVG=host vs graft 
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Table 3. Univariate analysis of OS and NRM in relation to HLA mismatched and 
other transplant variables. 
 
OS NRM 
Demographic and clinical 
characteristics 
HR (95% CI) p-value SHR (95% CI) p-value 
Total Mismatch (3-4 vs 0-1-2) 0.83 (0.44-1.59) 0.58 1.05 (0.38-2.93) 0.93 
Bidirectional Mismatch 
(4 vs 0-1-2-3) 
0.99 (0.70-1.41) 0.96 1.29 (0.77-2.13) 0.33 
Total Mismatch, continuous 1.01 (0.79-1.29) 0.95 1.06 (0.72-1.54) 0.78 
Gender, Male  1.04 (0.74-1.46) 0.83 1.03 (0.62-1.71) 0.92 
Age, 1-year increase 1.01 (0.99-1.02) 0.092 1.03 (1.01-1.05) 0.002 
Gender donor, Male  1.06 (0.74-1.50) 0.76 0.96 (0.57-1.60) 0.87 
Donor mother 0.77 (0.40-1.46) 0.42 0.16 (0.02-1.17) 0.071 
Disease  
 
0.58 
 
0.11 
-       AML 1.00 (ref) 
 
1.00 (ref) 
 
-       ALL 0.97 (0.61-1.56) 
 
0.41 (0.17-0.97) 
 
-       NHL 1.18 (0.60-2.31) 
 
0.67 (0.20-2.27) 
 
-       CLL 1.04 (0.38-2.87) 
 
0.89 (0.21-3.86) 
 
-       MM 1.12 (0.45-2.80) 
 
0.76 (0.18-3.30) 
 
-       MPD 1.35 (0.83-2.18) 
 
1.58 (0.84-2.96) 
 
-       MDS 0.63 (0.32-1.24) 
 
0.52 (0.19-1.45) 
 
Active disease at transplant 3.61 (2.50-5.21) <0.001 2.44 (1.44-4.15) <0.001 
TNC infused 1-unit increase 1.01 (0.88-1.17) 0.88 0.91 (0.73-1.13) 0.38 
AB0 major incompatibility 1.19 (0.79-1.79) 0.42 1.13 (0.61-2.07) 0.70 
CMV serology (donor/recipient) 
 
0.53 
 
0.17 
      +/+ 1.00 (ref) 
 
1.00 (ref) 
 
      +/- 0.86 (0.41-1.77) 
 
0.63 (0.20-1.98) 
 
      -/+ 0.99 (0.66-1.50) 
 
0.64 (0.34-1.23) 
 
      -/- 0.59 (0.27-1.28) 
 
0.16 (0.02-1.21) 
 
Conditioning regimen 
 
0.12 
 
0.18 
     TT Flu Bu (2 days) 1.00 (ref) 
 
1.00 (ref) 
 
     TT Flu Bu (3 days) 0.78 (0.52-1.16) 
 
0.88 (0.50-1.54) 
 
     TBI 330x3 Flu 1.06 (0.64-1.76) 
 
0.45 (0.16-1.30) 
 
     TBI 200x2 Flu 0.55 (0.22-1.39) 
 
0.51 (0.12-2.10) 
 
TT Flu Mel 1.81 (0.92-3.57)  1.93 (0.80-4.69)  
Abbreviations: AML=acute myeloidleukemia; ALL=acute lymphoblasticleukemia; 
NHL=non-Hodgkin’slymphoma; CLL=chroniclymphocyticleukemia; MM= multiple 
myeloma; MPD=myeloproliferative disease; MDS=myelodysplasticsyndrome; 
Page 24 of 30
25 
TNC=totalnucleatedcells; CMV=citomegalovirus; TT=thyotepa; Flu=fludarabine; 
Bu=busulfan; TBI=total body irradiation; Mel=melphalan 
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Tab 4. Multivariate analysis of OS, NRM, relapse and graft rejection. 
 
Variable* 
 
HR (95%CI) p 
OS 
    
 
Active disease at 
transplant 3.61 (2.50-5.21) <0.001 
NRM 
    
 
Age, 1-year increase 1.02 (1.00-1.04) 0.024 
 
Active diseaseattransplant 2.03 (1.18-3.50) 0.011 
Relapse 
    
 
Active diseaseattransplant 2.86 (1.87-4.38) <0.001 
 
Conditioning regimen    0.035 
  
     TT Flu Bu (2 days) 1.00 (ref)  
  
     TT Flu Bu (3 days) 1.16 (0.71-1.89)  
  
     TBI 330x3 Flu 2.47 (1.36-4.47) *** 
  
     TBI 200x2 Flu 0.79 (0.25-2.49)  
  
     TT Flu Mel 1.44 (0.71-2.94)  
GraftRejection 
 
    
 
Gender patient,  Male  
 
0.41 (0.16-1.07) 0.067  
 
Conditioning regimen    0.042 
  
     TT Flu Bu (2 days) 1.00 (ref)  
  
     TT Flu Bu (3 days) 0.18 (0.05-0.66)  
  
     TBI 330x3 Flu 0.21 (0.03-1.65)  
  
     TBI 200x2 Flu NE  
  
     TT Flu Mel 0.60 (0.12-3.07)  
 
Active disease at 
transplant 
 2.79 (1.00-7.85) 0.05 
*All variables with a p-value <=0.15 at univariable analysis were considered for the multivariable model. 
Only those significant were entered into the final multivariable model.  
 
Abbreviations: TT=thyotepa; Flu=fludarabine; Bu=busulfan; TBI=total body 
irradiation; Mel=melphalan. 
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Table 5. Univariate analysis of aGVHD, cGVHD and Relapse in relation to HLA 
mismatched (GvH direction) and other transplant variables. 
 
aGVHD cGVHD 
 
Relapse 
Demographic and clinical 
characteristics 
SHR (95% CI) 
p-
value 
SHR (95% CI) 
p-
value 
SHR (95% CI) 
p-
value 
Mismatch  GVH (3-4 vs 0-1-
2) 
2.02 (0.81-5.08) 0.13 1.11 (0.42-2.94) 0.84 0.74 (0.44-1.25) 0.26 
Mismatch GvH (4 vs 0-1-2-
3) 
1.37 (0.81-2.34) 0.24 0.80 (0.42-1.53) 0.51 0.92 (0.61-1.38) 0.69 
Total Mismatch GVH, 
continuous 
1.35 (0.98-1.87) 0.065 0.96 (0.68-1.34) 0.81 0.91 (0.74-1.13) 0.41 
Gender, Male  0.89 (0.53-1.51) 0.67 1.27 (0.66-2.44) 0.47 1.03 (0.69-1.54) 0.89 
Age, 1-year increase 1.01 (0.99-1.03) 0.22 1.00 (0.98-1.02) 0.81 0.99 (0.98-1.01) 0.25 
Gender donor, Male  0.81 (0.47-1.38) 0.44 0.77 (0.40-1.46) 0.42 1.14 (0.76-1.73) 0.53 
Donor mother 0.85 (0.30-2.40) 0.76 0.90 (0.28-2.89) 0.85 1.28 (0.68-2.43) 0.45 
Disease  
 
0.94 
 
0.55  0.14 
-       AML 1.00 (ref) 
 
1.00 (ref) 
 
1.00 (ref)  
-       ALL 1.03 (0.51-2.08) 
 
1.36 (0.58-3.15) 
 
1.85 (1.08-3.16)  
-       NHL 0.51 (0.12-2.24) 
 
0.54 (0.08-3.86) 
 
1.50 (0.66-3.42)  
-       CLL 1.81 (0.37-8.98) 
 
Notestimable 
 
1.91 (0.62-5.90)  
-       MM 0.83 (0.20-3.45) 
 
1.67 (0.40-6.99) 
 
2.25 (1.02-4.95)  
-       MPD 1.06 (0.50-2.25) 
 
1.19 (0.41-3.43) 
 
1.22 (0.66-2.28)  
-       MDS 0.82 (0.32-2.15) 
 
2.04 (0.82-5.09) 
 
0.83 (0.37-1.83)  
Active disease at transplant 0.91 (0.53-1.54) 0.71 1.20 (0.63-2.31) 0.58 2.68 (1.76-4.07) <0.001 
TNC infused 1-unit increase 1.01 (0.78-1.30) 0.95 1.04 (0.79-1.36) 0.79 1.04 (0.86-1.25) 0.70 
AB0 major incompatibility 1.29 (0.72-2.34) 0.38 1.32 (0.62-2.80) 0.48 1.24 (0.76-2.03) 0.39 
CMV serology 
(donor/recipient)  
0.39 
 
0.14  0.45 
      +/+ 1.00 (ref) 
 
1.00 (ref) 
 
1.00 (ref)  
      +/- 1.22 (0.48-3.06) 
 
0.62 (0.15-2.63) 
 
1.28 (0.61-2.69)  
      -/+ 0.53 (0.24-1.18) 
 
0.25 (0.07-0.83) 
 
1.42 (0.89-2.27)  
      -/- 1.16 (0.49-2.75) 
 
0.67 (0.21-2.14) 
 
0.88 (0.38-2.07)  
Conditioning regimen 
 
0.98 
 
0.89  0.05 
     TT Flu Bu (2 days) 1.00 (ref) 
 
1.00 (ref) 
 
1.00 (ref)  
     TT Flu Bu (3 days) 1.01 (0.55-1.86) 
 
1.20 (0.56-2.56) 
 
1.02 (0.63-1.67)  
     TBI 330x3 Flu 1.15 (0.49-2.70) 
 
1.36 (0.48-3.85) 
 
1.89 (1.06-3.37)  
     TBI 200x2 Flu 1.27 (0.44-3.68) 
 
1.72 (0.50-5.87) 
 
0.60 (0.18-1.97)  
 TT Flu Mel 1.26 (0.38-4.22)  1.63 (0.39-6.94)  1.96 (0.95-4.02)  
Abbreviations: AML=acute myeloidleukemia; ALL=acute lymphoblasticleukemia; 
NHL=non-Hodgkin’slymphoma; CLL=chroniclymphocyticleukemia; MM= multiple 
myeloma; MPD=myeloproliferative disease; MDS=myelodysplasticsyndrome; 
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TNC=totalnucleatedcells; CMV=citomegalovirus; TT=thyotepa; Flu=fludarabine; 
Bu=busulfan; TBI=total body irradiation; Mel=melphalan 
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Table 6 Univariate analysis of graft rejection in relation to HLA mismatched 
(HvG)  and other transplant variables. 
 
Graftrejection 
Demographic and clinical characteristics OR (95% CI) p-value 
 Mismatch HGV (3-4 vs 0-1-2) 1.02 (0.29-3.60) 0.98 
Mismatch HGV (4 vs 0-1-2-3) 1.47 (0.58-3.76) 0.42 
Total Mismatch, continuous 0.95 (0.59-1.52) 0.83 
Gender, Male  0.50 (0.20-1.24) 0.13 
Age, 1-year increase 1.05 (1.01-1.09) 0.022 
Gender donor, Male  2.17 (0.77-6.08) 0.12 
Donor age, 1 year increase 0.99(0.96 – 1.03) 0.75 
Donor mother 1.15 (0.25-5.20) 0.86 
Disease   0.21 
-       AML 1.00 (ref)  
-       ALL 0.57 (0.11-2.81)  
-       LNH NE  
-       CLL 4.39 (0.78-24.69)  
-       MM 3.19 (0.59-17.28)  
-       MPD 2.51 (0.80-7.89)  
-       MDS 1.13 (0.22-5.73)  
Active disease at transplant 3.26 (1.23-8.62) 0.018 
TNC infused 1-unit increase 0.84 (0.56-1.28) 0.42 
AB0 major incompatibility 0.42 (0.09-1.83) 0.25 
CMV serology (donor/recipient)  0.14 
      +/+ 1.00 (ref)  
      +/- 0.53 (0.07-4.21)  
      -/+ 0.28 (0.06-1.26)  
      -/- NE  
Conditioning regimen  0.0078 
     TT Flu Bu (2 days) 1.00 (ref)  
     TT Flu Bu (3 days) 0.17 (0.05-0.61)  
     TBI 330x3 Flu 0.19 (0.02-1.48)  
     TBI 200x2 Flu NE  
  TT Flu Mel 0.93 (0.19-4.49)  
Abbreviations: AML=acute myeloidleukemia; ALL=acute lymphoblasticleukemia; 
NHL=non-Hodgkin’slymphoma; CLL=chroniclymphocyticleukemia; MM= multiple 
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myeloma; MPD=myeloproliferative disease; MDS=myelodysplasticsyndrome; 
TNC=totalnucleatedcells; CMV=citomegalovirus; NE = notevaluable; TT=thyotepa; 
Flu=fludarabine; Bu=busulfan; TBI=total body irradiation; Mel=melphalan 
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